Article
Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Aug 2011
de Graan Anne-Joy M, Teunissen Sebastiaan F, de Vos Filip Y F L, Loos Walter J, van Schaik Ron H N, de Jongh Felix E, de Vos Aad I, van Alphen Robbert J, van der Holt Bronno, Verweij Jaap, Seynaeve Caroline, Beijnen Jos H, Mathijssen Ron H J
Abstract excerpt
PURPOSE: Tamoxifen, a widely used agent for the prevention and treatment of breast cancer, is mainly metabolized by CYP2D6 and CYP3A to form its most abundant active metabolite, endoxifen. Interpatient variability in toxicity and efficacy of tamoxifen is substantial. Contradictory results on the value of CYP2D6 genotyping to reduce the variable efficacy have been reported. In this pharmacokinetic study, we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.